In vitro activity of quinupristin/dalfopristin and newer quinolones combined with gentamicin against resistant isolates of Enterococcus faecalis and Enterococcus faecium

Eur J Clin Microbiol Infect Dis. 1998 Sep;17(9):657-61. doi: 10.1007/BF01708351.

Abstract

In a study designed to obtain data on compounds active against enterococci, the minimum inhibitory concentrations (MICs) of quinupristin/dalfopristin (RP 59500) and the novel quinolones DU-6859a, trovafloxacin, levofloxacin, and sparfloxacin were determined for 122 Enterococcus faecalis and seven Enterococcus faecium isolates. In addition, 15 Enterococcus faecalis isolates resistant to gentamicin, DU-6859a, and trovafloxacin were exposed over time to combinations of DU-6859a plus gentamicin and trovafloxacin plus gentamicin. DU-6859a and trovafloxacin were found to be the most active compounds against Enterococcus faecalis and DU-6859a and RP 59500 against Enterococcus faecium. Synergy between either DU-6859a or trovafloxacin and gentamicin was observed with 27 to 35% of the isolates. It is concluded that DU-6859a and trovafloxacin are very potent against enterococci, especially when combined with gentamicin.

MeSH terms

  • Anti-Bacterial Agents / pharmacology*
  • Anti-Infective Agents / pharmacology*
  • Drug Resistance, Microbial
  • Drug Synergism
  • Drug Therapy, Combination / pharmacology
  • Enterococcus faecalis / drug effects*
  • Enterococcus faecium / drug effects*
  • Fluoroquinolones*
  • Gentamicins / pharmacology*
  • Levofloxacin
  • Microbial Sensitivity Tests
  • Naphthyridines / pharmacology
  • Ofloxacin / pharmacology
  • Quinolones / pharmacology
  • Virginiamycin / pharmacology*

Substances

  • Anti-Bacterial Agents
  • Anti-Infective Agents
  • Fluoroquinolones
  • Gentamicins
  • Naphthyridines
  • Quinolones
  • Virginiamycin
  • quinupristin-dalfopristin
  • Levofloxacin
  • trovafloxacin
  • sitafloxacin
  • Ofloxacin
  • sparfloxacin